European Heart Journal最新文献

筛选
英文 中文
Updated declaration of interests for European Society of Cardiology volunteers and officers. 欧洲心脏病学会志愿者和官员的最新利益声明。
IF 39.3 1区 医学
European Heart Journal Pub Date : 2024-09-25 DOI: 10.1093/eurheartj/ehae663
Carlos Aguiar,Paulus Kirchhof,Franz Weidinger
{"title":"Updated declaration of interests for European Society of Cardiology volunteers and officers.","authors":"Carlos Aguiar,Paulus Kirchhof,Franz Weidinger","doi":"10.1093/eurheartj/ehae663","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae663","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":39.3,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142321421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravascular ultrasound improves the outcomes of drug-coated balloon angioplasty by providing precise vessel dimensions for optimal device size selection. 血管内超声可提供精确的血管尺寸,以便选择最佳的器械尺寸,从而改善药物涂层球囊血管成形术的效果。
IF 39.3 1区 医学
European Heart Journal Pub Date : 2024-09-25 DOI: 10.1093/eurheartj/ehae622
Young-Guk Ko
{"title":"Intravascular ultrasound improves the outcomes of drug-coated balloon angioplasty by providing precise vessel dimensions for optimal device size selection.","authors":"Young-Guk Ko","doi":"10.1093/eurheartj/ehae622","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae622","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":39.3,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is intravascular ultrasound needed to optimize drug-coated balloon angioplasty results? 是否需要血管内超声来优化药物涂层球囊血管成形术的效果?
IF 39.3 1区 医学
European Heart Journal Pub Date : 2024-09-25 DOI: 10.1093/eurheartj/ehae621
Fernando Alfonso,Bernardo Cortese
{"title":"Is intravascular ultrasound needed to optimize drug-coated balloon angioplasty results?","authors":"Fernando Alfonso,Bernardo Cortese","doi":"10.1093/eurheartj/ehae621","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae621","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":39.3,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142320992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex-specific differences in alive hospital discharge following infrarenal abdominal aortic aneurysm repair. 肾下腹主动脉瘤修补术后出院存活率的性别差异。
IF 37.6 1区 医学
European Heart Journal Pub Date : 2024-09-24 DOI: 10.1093/eurheartj/ehae675
Anna Louise Pouncey, Michael J Sweeting, Colin Bicknell, Janet T Powell, Jenny Lübcke, Kim Gunnarsson, Anders Wanhainen, Kevin Mani
{"title":"Sex-specific differences in alive hospital discharge following infrarenal abdominal aortic aneurysm repair.","authors":"Anna Louise Pouncey, Michael J Sweeting, Colin Bicknell, Janet T Powell, Jenny Lübcke, Kim Gunnarsson, Anders Wanhainen, Kevin Mani","doi":"10.1093/eurheartj/ehae675","DOIUrl":"10.1093/eurheartj/ehae675","url":null,"abstract":"<p><strong>Background and aims: </strong>A longer time to alive hospital discharge following infrarenal abdominal aortic aneurysm (AAA) repair is associated with reduced patient-satisfaction and increased length of stay, hospital-acquired deconditioning, infection and costs. This study investigated sex-specific differences in, and drivers of, the rate of alive hospital discharge.</p><p><strong>Methods: </strong>Examination of UK National Vascular Registry (UK NVR), 2014-2019 and Swedish National Patient Registry (SE NPR) elective AAA patients, 2010-2018, for endovascular (EVAR) or open (OAR) aneurysm repair. Cox models assessed sex-specific difference in rate of alive hospital discharge, adjusting for co-morbidity, anatomy, standard-of-care, post-operative complications, and year, with in-hospital death as the competing risk.</p><p><strong>Results: </strong>29,751 AAA repairs (UK NVR -EVAR 12518:1532; OAR 6803:837; SE NPR - EVAR 4234:792; OAR 2638:497, men:women) were assessed. For EVAR, the unadjusted rate of alive hospital discharge was ∼25% lower for women (UK NVR HR 0.75 [0.71-0.80], p<.001; SE NPR HR 0.75 [0.69-0.81], p<.001). Following adjustment the sex-specific hazard ratio narrowed but remained significant (UK NVR: HR 0.83 [0.79-0.88], p<.001; SE NPR HR 0.83 [0.76-0.89], p<.001). For OAR, the rate of alive hospital discharge was 23-27% lower for women (UK NVR HR 0.73 [0.67-0.78], p<.001; SE NPR HR 0.77 [0.70-0.85], p<.001). Following adjustment the sex-specific hazard ratio narrowed (UK NVR HR 0.82 [0.76-0.88], p<.001; SE NPR HR 0.79 [0.72-0.88], p<.001) but remained significant.</p><p><strong>Conclusions: </strong>Women have a 25% lower rate of alive discharge after aortic surgery, despite adjustment for pre/peri- and postoperative parameters. Efforts to increase rate of alive hospital discharge for women should be sought.</p>","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":37.6,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of ventricular arrhythmia in early post-infarction left ventricular dysfunction: the French nationwide WICD-MI study. 心梗后早期左心室功能障碍中室性心律失常的预后价值:法国全国性 WICD-MI 研究。
IF 39.3 1区 医学
European Heart Journal Pub Date : 2024-09-20 DOI: 10.1093/eurheartj/ehae575
Mathieu Echivard,Jean-Marc Sellal,Chloé Ziliox,Eloi Marijon,Pierre Bordachar,Sylvain Ploux,Karim Benali,Christelle Marquié,Clémence Docq,Didier Klug,Romain Eschalier,Baptiste Maille,Jean-Claude Deharo,Dominique Babuty,Thibaud Genet,Estelle Gandjbakhch,Antoine Da Costa,Olivier Piot,Damien Minois,Jean-Baptiste Gourraud,Pierre Mondoly,Philippe Maury,Serge Boveda,Jean-Luc Pasquié,Raphaël Martins,Christophe Leclercq,Charles Guenancia,Gabriel Laurent,Mathieu Becker,Julien Bertrand,Philippe Chevalier,Vladimir Manenti,Maciej Kubala,Pascal Defaye,Peggy Jacon,Antoine Desbiolles,Marc Badoz,Laurence Jesel,Nicolas Lellouche,Paul-Ursmar Milliez,Paul Ollitrault,Samir Fareh,Matthieu Bercker,Jacques Mansourati,Benoît Guy-Moyat,Jean-Pierre Chabert,Nicolas Luconi,Pierre-François Winum,Frédéric Anselme,Fabrice Extramiana,Camille Delahaye,François Jourda,Olivier Bizeau,Mathieu Nasarre,Arnaud Olivier,Stéphane Fromentin,Thibault Villemin,Olivier Levavasseur,Néfissa Hammache,Isabelle Magnin-Poull,Hugues Blangy,Nicolas Sadoul,Kevin Duarte,Nicolas Girerd,Christian de Chillou
{"title":"Prognostic value of ventricular arrhythmia in early post-infarction left ventricular dysfunction: the French nationwide WICD-MI study.","authors":"Mathieu Echivard,Jean-Marc Sellal,Chloé Ziliox,Eloi Marijon,Pierre Bordachar,Sylvain Ploux,Karim Benali,Christelle Marquié,Clémence Docq,Didier Klug,Romain Eschalier,Baptiste Maille,Jean-Claude Deharo,Dominique Babuty,Thibaud Genet,Estelle Gandjbakhch,Antoine Da Costa,Olivier Piot,Damien Minois,Jean-Baptiste Gourraud,Pierre Mondoly,Philippe Maury,Serge Boveda,Jean-Luc Pasquié,Raphaël Martins,Christophe Leclercq,Charles Guenancia,Gabriel Laurent,Mathieu Becker,Julien Bertrand,Philippe Chevalier,Vladimir Manenti,Maciej Kubala,Pascal Defaye,Peggy Jacon,Antoine Desbiolles,Marc Badoz,Laurence Jesel,Nicolas Lellouche,Paul-Ursmar Milliez,Paul Ollitrault,Samir Fareh,Matthieu Bercker,Jacques Mansourati,Benoît Guy-Moyat,Jean-Pierre Chabert,Nicolas Luconi,Pierre-François Winum,Frédéric Anselme,Fabrice Extramiana,Camille Delahaye,François Jourda,Olivier Bizeau,Mathieu Nasarre,Arnaud Olivier,Stéphane Fromentin,Thibault Villemin,Olivier Levavasseur,Néfissa Hammache,Isabelle Magnin-Poull,Hugues Blangy,Nicolas Sadoul,Kevin Duarte,Nicolas Girerd,Christian de Chillou","doi":"10.1093/eurheartj/ehae575","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae575","url":null,"abstract":"BACKGROUND AND AIMSProphylactic implantable cardioverter-defibrillators (ICDs) are not recommended until left ventricular ejection fraction (LVEF) has been reassessed 40 to 90 days after an acute myocardial infarction. In the current therapeutic era, the prognosis of sustained ventricular arrhythmias (VAs) occurring during this early post-infarction phase (i.e. within 3 months of hospital discharge) has not yet been specifically evaluated in post-myocardial infarction patients with impaired LVEF. Such was the aim of this retrospective study.METHODSData analysis was based on a nationwide registry of 1032 consecutive patients with LVEF ≤ 35% after acute myocardial infarction who were implanted with an ICD after being prescribed a wearable cardioverter-defibrillator (WCD) for a period of 3 months upon discharge from hospital after the index infarction.RESULTSICDs were implanted either because a sustained VA occurred while on WCD (VA+/WCD, n = 72) or because LVEF remained ≤35% at the end of the early post-infarction phase (VA-/WCD, n = 960). The median follow-up was 30.9 months. Sustained VAs occurred within 1 year after ICD implantation in 22.2% and 3.5% of VA+/WCD and VA-/WCD patients, respectively (P < .0001). The adjusted multivariable analysis showed that sustained VAs while on WCD independently predicted recurrence of sustained VAs at 1 year (adjusted hazard ratio [HR] 6.91; 95% confidence interval [CI] 3.73-12.81; P < .0001) and at the end of follow-up (adjusted HR 3.86; 95% CI 2.37-6.30; P < .0001) as well as 1-year mortality (adjusted HR 2.86; 95% CI 1.28-6.39; P = .012).CONCLUSIONSIn patients with LVEF ≤ 35%, sustained VA during the early post-infarction phase is predictive of recurrent sustained VAs and 1-year mortality.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":39.3,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142273419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. 更正:伊维那单抗治疗同型家族性高胆固醇血症:长期安全性和有效性。
IF 39.3 1区 医学
European Heart Journal Pub Date : 2024-09-20 DOI: 10.1093/eurheartj/ehae594
{"title":"Correction to: Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy.","authors":"","doi":"10.1093/eurheartj/ehae594","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae594","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":39.3,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142275281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Weekly Journal Scan: tirzepatide SURMOUNTs obesity-related obstructive sleep apnoea. 每周期刊扫描:替唑帕肽 SURMOUNTs 肥胖相关性阻塞性睡眠呼吸暂停。
IF 39.3 1区 医学
European Heart Journal Pub Date : 2024-09-20 DOI: 10.1093/eurheartj/ehae568
Giovanna Liuzzo,Carlo Patrono
{"title":"Weekly Journal Scan: tirzepatide SURMOUNTs obesity-related obstructive sleep apnoea.","authors":"Giovanna Liuzzo,Carlo Patrono","doi":"10.1093/eurheartj/ehae568","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae568","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":39.3,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142275212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful management of cardiac hydatidosis complicated by rupture and embolism. 成功治疗心脏包虫病并发破裂和栓塞。
IF 39.3 1区 医学
European Heart Journal Pub Date : 2024-09-18 DOI: 10.1093/eurheartj/ehae605
Daniel Barnés-Navarro,Gerard Martí-Aguasca,Aitor Uribarri
{"title":"Successful management of cardiac hydatidosis complicated by rupture and embolism.","authors":"Daniel Barnés-Navarro,Gerard Martí-Aguasca,Aitor Uribarri","doi":"10.1093/eurheartj/ehae605","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae605","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":39.3,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142245402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical features and outcomes in carriers of pathogenic desmoplakin variants 致病性去鳞屑变体携带者的临床特征和预后
IF 39.3 1区 医学
European Heart Journal Pub Date : 2024-09-17 DOI: 10.1093/eurheartj/ehae571
Alessio Gasperetti, Richard T Carrick, Alexandros Protonotarios, Brittney Murray, Mikael Laredo, Iris van der Schaaf, Ronald H Lekanne, Petros Syrris, Douglas Cannie, Crystal Tichnell, Chiara Cappelletto, Marta Gigli, Kristen Medo, Ardan M Saguner, Firat Duru, Nisha A Gilotra, Stefan Zimmerman, Robyn Hylind, Dominic J Abrams, Neal K Lakdawala, Julia Cadrin-Tourigny, Mattia Targetti, Iacopo Olivotto, Maddalena Graziosi, Moniek Cox, Elena Biagini, Philippe Charron, Michela Casella, Claudio Tondo, Momina Yazdani, James S Ware, Sanjay K Prasad, Leonardo Calò, Eric D Smith, Adam S Helms, Sophie Hespe, Jodie Ingles, Harikrishna Tandri, Flavie Ader, Giovanni Peretto, Stacey Peters, Ari Horton, Jess Yao, Sven Dittmann, Eric Schulze-Bahr, Maria Qureshi, Katelyn Young, Eric D Carruth, Chris Haggerty, Victoria N Parikh, Matthew Taylor, Luisa Mestroni, Arthur Wilde, Gianfranco Sinagra, Marco Merlo, Estelle Gandjbakhch, J Peter van Tintelen, Anneline S J M te Riele, Perry M Elliott, Hugh Calkins, Cynthia A James
{"title":"Clinical features and outcomes in carriers of pathogenic desmoplakin variants","authors":"Alessio Gasperetti, Richard T Carrick, Alexandros Protonotarios, Brittney Murray, Mikael Laredo, Iris van der Schaaf, Ronald H Lekanne, Petros Syrris, Douglas Cannie, Crystal Tichnell, Chiara Cappelletto, Marta Gigli, Kristen Medo, Ardan M Saguner, Firat Duru, Nisha A Gilotra, Stefan Zimmerman, Robyn Hylind, Dominic J Abrams, Neal K Lakdawala, Julia Cadrin-Tourigny, Mattia Targetti, Iacopo Olivotto, Maddalena Graziosi, Moniek Cox, Elena Biagini, Philippe Charron, Michela Casella, Claudio Tondo, Momina Yazdani, James S Ware, Sanjay K Prasad, Leonardo Calò, Eric D Smith, Adam S Helms, Sophie Hespe, Jodie Ingles, Harikrishna Tandri, Flavie Ader, Giovanni Peretto, Stacey Peters, Ari Horton, Jess Yao, Sven Dittmann, Eric Schulze-Bahr, Maria Qureshi, Katelyn Young, Eric D Carruth, Chris Haggerty, Victoria N Parikh, Matthew Taylor, Luisa Mestroni, Arthur Wilde, Gianfranco Sinagra, Marco Merlo, Estelle Gandjbakhch, J Peter van Tintelen, Anneline S J M te Riele, Perry M Elliott, Hugh Calkins, Cynthia A James","doi":"10.1093/eurheartj/ehae571","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae571","url":null,"abstract":"Background and Aims Pathogenic variants in the desmoplakin (DSP) gene are associated with the development of a distinct arrhythmogenic cardiomyopathy phenotype not fully captured by either dilated cardiomyopathy (DCM), non-dilated left ventricular cardiomyopathy (NDLVC), or arrhythmogenic right ventricular cardiomyopathy (ARVC). Prior studies have described baseline DSP cardiomyopathy genetic, inflammatory, and structural characteristics. However, cohort sizes have limited full clinical characterization and identification of clinical and demographic predictors of sustained ventricular arrhythmias (VAs), heart failure (HF) hospitalizations, and transplant/death. In particular, the relevance of acute myocarditis-like episodes for subsequent disease course is largely unknown. Methods All patients with pathogenic/likely pathogenic (P/LP) DSP variants in the worldwide DSP-ERADOS Network (26 academic institutions across nine countries) were included. The primary outcomes were the development of sustained VA and HF hospitalizations during follow-up. Fine–Gray regressions were used to test association between clinical and instrumental parameters and the development of outcomes. Results Eight hundred patients [40.3 ± 17.5 years, 47.5% probands, left ventricular ejection fraction (LVEF) 49.5 ± 13.9%] were included. Over 3.7 [1.4–7.1] years, 139 (17.4%, 3.9%/year) and 72 (9.0%, 1.8%/year) patients experienced sustained VA and HF episodes, respectively. A total of 32.5% of individuals did not fulfil diagnostic criteria for ARVC, DCM, or NDLVC; their VA incidence was 0.5%/year. In multivariable regression, risk features associated with the development of VA were female sex [adjusted hazard ratio (aHR) 1.547; P = .025], prior non-sustained ventricular tachycardia (aHR 1.721; P = .009), prior sustained VA (aHR 1.923; P = .006), and LVEF ≤ 50% (aHR: 1.645; P = .032), while for HF, they were the presence of T-wave inversion in 3+ electrocardiogram leads (aHR 2.036, P = .007) and LVEF ≤ 50% (aHR 3.879; P &amp;lt; .001). Additionally, 70 (8.8%) patients experienced a myocardial injury episode at presentation or during follow-up. These episodes were associated with an increased risk of VA and HF thereafter (HR 2.394; P &amp;lt; .001, and HR 5.064, P &amp;lt; .001, respectively). Conclusions Patients with P/LP DSP variants experience high rates of sustained VA and HF hospitalizations. These patients demonstrate a distinct clinical phenotype (DSP cardiomyopathy), whose most prominent risk features associated with adverse clinical outcomes are the presence of prior non-sustained ventricular tachycardia or sustained VA, T-wave inversion in 3+ leads on electrocardiogram, LVEF ≤ 50%, and myocardial injury events.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":39.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142236876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Traditional Chinese medicine: cardiovascular drug development through a holistic framework. 中药:通过整体框架开发心血管药物。
IF 39.3 1区 医学
European Heart Journal Pub Date : 2024-09-17 DOI: 10.1093/eurheartj/ehae625
Milton Packer
{"title":"Traditional Chinese medicine: cardiovascular drug development through a holistic framework.","authors":"Milton Packer","doi":"10.1093/eurheartj/ehae625","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae625","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":39.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142245459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信